FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					or S	ection 3	30(h) of th	ne Investm	ent C	ompany Act o	of 1940							
1. Name and Address of Reporting Person* <u>Struthers Richard Scott</u>						2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX]								5. Relationship of Reporting Person(s) to Issu (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) X 07/11/2023								Officer (give title below) Other (specify below) President & CEO				
10222 BARNES CANYON ROAD, BLDG 2				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Ind Line)									ndividual or Joint/Group Filing (Check Applicable				
(Street) SAN DIEGO CA 92121					X									Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication														
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Table	I - N	on-Derivat	tive	Secui	rities A	cquired	d, Di	sposed of	f, or B	enefic	ially	Owr	ned			
Date				2. Transactio Date (Month/Day/Y		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code (I		4. Securities Disposed O 5)	urities Acquired (A) or sed Of (D) (Instr. 3, 4 and				5. Amount of Securities Beneficially Owned Following		rect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price		Report Transa (Instr.	ted action(s) 3 and 4)	(Instr. 4)		` ,
Common	Stock			07/11/202	23			S		24,384	D	\$20.1	4(1)	65	66,421	I		By Family Trust 1
Common Stock			07/12/2023		3		S		11,459	D	\$20.1	0.17(2)		644,962			By Family Trust 1	
Common	Stock			07/13/202	23			S		14,157	D	\$20.3	35 ⁽³⁾	63	80,805	I		By Family Trust 1
Common	Stock													12	25,522	D		
Common	Stock													1	,000	I		By Spouse
Common	Stock													90	0,000	I		By Family Trust 2
Common Stock												90,000		I		By Family Trust 3		
Common Stock												90,000		I		By Family Trust 4		
		Та	ble II	- Derivativ (e.g., put						oosed of, convertib				Owne	ed			'
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Conversion or Exercise (Month/Day/Year) Price of Derivative				saction (Instr.	5.	6. Dat Expira (Mont	e Exe	rcisable and Date	7. Title Amour Securit Underl Derivat Securit	and nt of ties ying tive	8. Pi Deri Sec	rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owi Fori y Dire or li (I) (I	nership n: ect (D) ndirect nstr. 4)	Beneficial Ownershi (Instr. 4)
					Code	· V	(A) (E	Date Exerc	isable	Expiration Date		Amount or Number of Shares						

Explanation of Responses:

- 2. The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of \$20.17 per share. The range of sales prices on the transaction date was \$20.10 to \$20.31 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- 3. The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of \$20.35 per share. The range of sales prices on the transaction date was \$20.10 to \$20.68 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

Remarks:

/s/ Marc Wilson, as attorneyin-fact 07/13/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.